Home | Welcome to Contract Pharma   
Last Updated Saturday, May 23 2015


Shire’s Lexington Facility Approved for VPRIV Product

By Kristin Brooks

Published February 14, 2014
Shire plc received approval from the FDA for the production of VPRIV drug substance (velaglucerase alfa for injection) at its manufacturing facility in Lexington, MA. The facility was previously approved by the EMA for production of VPRIV drug substance.
Shire has invested more than $200 million in manufacturing infrastructure and technology to establish a consistent drug supply chain for this treatment. The facility is the first commercially licensed facility to use single-use bioreactor and disposable technology throughout cell culture processing designed to reduce manufacturing risk.
"Shire has always been committed to providing uninterrupted treatment for all VPRIV patients at the dose and frequency prescribed by their physicians. We continue to deliver on this commitment," said Bill Ciambrone, executive vice president, Technical Operations, Shire.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On